Emily Atkinson(@dremilyatkinson) 's Twitter Profileg
Emily Atkinson

@dremilyatkinson

Chief hematology/oncology fellow at NYU Long Island @NYULISOM_HemOnc. Alum @NYULH_DeptofMed @TuftsMedSchool @holy_cross. Tweets are my own

ID:1552332099100852224

calendar_today27-07-2022 16:37:37

16 Tweets

21 Followers

54 Following

Emily Atkinson(@dremilyatkinson) 's Twitter Profile Photo

Colleagues and I have lamented how our attention spans have decreased during our training. All the pages, Epic messages, phone calls, have made us scattered, so it’s harder to focus than in med school. How can we reverse this trend when tech is now so integral to our work as MDs?

account_circle
Emily Atkinson(@dremilyatkinson) 's Twitter Profile Photo

Another educational . We take one step towards improved cancer treatment (and ultimately cure) every year!

“There is no need to worry even if you see a mountain before you.

It is not that you are walking towards the mountain.

It is that you are walking towards the future.”

Another educational #CFS. We take one step towards improved cancer treatment (and ultimately cure) every year! “There is no need to worry even if you see a mountain before you. It is not that you are walking towards the mountain. It is that you are walking towards the future.”
account_circle
Yan Leyfman, MD(@YLeyfman) 's Twitter Profile Photo

Great presentation about the latest developments for transplant by 🌟Dr. Marc Braunstein 🌟 from NYU at the 41st Annual CFS Conference.

Great presentation about the latest developments for transplant by 🌟Dr. Marc Braunstein 🌟 from NYU at the 41st Annual CFS Conference.
account_circle
Oncology Brothers(@OncBrothers) 's Twitter Profile Photo

is now FDA Oncology approved based in refractory mCRC (discussed this w/ Dr. Cathy Eng previously, link👇).

- mOS 7.4mos vs 4.8mos (HR=0.66)
- ORR: 16% vs 1.5%
- mPFS 3.7mos vs 1.8mos
- New treatment option for our refractory mCRC Pts!

#Fruquintinib is now @FDAOncology approved based #FRESCO2 in refractory mCRC (discussed this w/ @CathyEngMD previously, link👇). - mOS 7.4mos vs 4.8mos (HR=0.66) - ORR: 16% vs 1.5% - mPFS 3.7mos vs 1.8mos - New treatment option for our refractory mCRC Pts! #crcsm #OncTwitter
account_circle
Emily Atkinson(@dremilyatkinson) 's Twitter Profile Photo

So proud of our amazing program director who is an incredible educator, researcher, and clinician 💯 If anyone deserves this award, he does

account_circle
Emily Atkinson(@dremilyatkinson) 's Twitter Profile Photo

Hopeful news. All patients deserve an in-depth, face-to-face conversation about a new or recurrent cancer diagnosis. Not a ping to their phone they are left to interpret on their own.

account_circle
ASCO(@ASCO) 's Twitter Profile Photo

“Opinion: The cancer drug shortage is a disgrace” -- read a just-published CNN op-ed from our Board Chair & Past President Eric Winer, MD on the current oncology : fal.cn/3AtEQ

account_circle
Emily Atkinson(@dremilyatkinson) 's Twitter Profile Photo

Such a wonderful time at my first in-person ASCO Annual Meeting. So much learning and camaraderie! Already eagerly anticipating ASCO 2024

Such a wonderful time at my first in-person @ASCO Annual Meeting. So much learning and camaraderie! Already eagerly anticipating ASCO 2024
account_circle